Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 944-947, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haese, A.
Right arrow Articles by Chan, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haese, A.
Right arrow Articles by Chan, D. W.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2002;48:944-947.)
© 2002 American Association for Clinical Chemistry, Inc.

Technical Briefs

Clinical Evaluation of the Elecsys Total Prostate-specific Antigen Assay on the Elecsys 1010 and 2010 Systems

Alexander Haese1, Robert T. Dworschack3, Steven P. Piccoli4, Lori J. Sokoll2, Alan W. Partin1a and Daniel W. Chan2

1 The James Buchanan Brady Urological Institute and
2 The Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287

3 Roche Diagnostics, Indianapolis, IN 46256

4 Diagnostic Oncology, Seymour, CT 06483

aaddress correspondence to this author at: The Johns Hopkins University School of Medicine, James Buchanan Brady Urological Institute, 600 N. Wolfe St., Baltimore, MD 21287; fax 410-614-8096, e-mail apartin@jhmi.edu

Prostate cancer (PCa) is a leading cause of cancer-related deaths. The American Cancer Society expects >198 000 newly diagnosed cases and 31 500 deaths related to PCa in the US in 2001 (1).

The indolent clinical course of PCa makes its early detection a challenge. Symptoms typically do not occur until PCa is locally advanced or metastasized, at which time cure is not usually possible. Early detection is therefore mandatory to reduce the mortality of PCa. Prostate-specific antigen (PSA) is a serine protease synthesized in prostatic epithelium. Introduced into clinical use in the late 1980s (2), PSA today is recognized as the most useful tumor marker in urologic oncology and as indispensable for early detection, staging, and monitoring of PCa (3).

Digital rectal examination (DRE) alone has a poor sensitivity of 2.2–25% (4)(5) and specificity of 39% (6) in detecting PCa. Measurement of serum PSA concentrations in combination with DRE markedly improves the detection of PCa and increases the lead time for diagnosis (4)(5).

This clinical study was designed to demonstrate the clinical utility of the newly developed Roche Diagnostics Elecsys® total PSA Assay on the Roche/Hitachi Elecsys 2010 and 1010 systems. This assay is a quantitative in vitro diagnostic test for detection of total PSA (tPSA) and is indicated for measurement of tPSA in combination with DRE to aid in the diagnosis of PCa.

A total of 1121 serum samples for PSA analysis were prospectively taken from men referred for urologic evaluation (mean age, 66 years; range, 50–91 years). DRE was performed by urologists. Symptoms leading to referral were, e.g., voiding dysfunction, lower back pain, or perineal discomfort. No previous PSA values were available, nor had any patient undergone a previous biopsy. No . . . [Full Text of this Article]


Acknowledgments


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.